Pomalidomide: A novel drug to treat relapsed and refractory multiple myeloma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 531-538

  Terpos, Evangelos ^a   Kanellias, Nikolaos ^a   Christoulas, Dimitrios ^a   Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Cereblon; Immunomodulatory drugs; Lenalidomide; Refractory

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; INTERLEUKIN 12; INTERLEUKIN 2; LENALIDOMIDE; POMALIDOMIDE; PROTEIN CEREBLON; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BACKACHE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL TOXICITY; GLUCOSE INTOLERANCE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREMOR; URINARY TRACT INFECTION;

EID: 84877914701     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S34498     Document Type: Review

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-300.
2. Kyle RA, Rajkumar S V. Multiple myeloma. N Engl J Med. 2004; 351(18):1860-1873.
3. Laubach J P, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011;4(1):51-60.
4. van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266-283.
5. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21):1565-1571.
6. Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol. 2005;42(4 Suppl 4):S3-S8.
7. Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C] pomalidomide in humans following oral administration. Cancer Chemother Pharmacol. 2013;71(2):489-501.
8. Rajkumar S V, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28(6):560-564.
9. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36-45.
10. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87(10):1166-1172.
11. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005;23(23):5334-5346.
12. Dredge K, Horsfall R, Robinson S P, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1-2):56-63.
13. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
14. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525-4530.
15. Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 1994; 55(2):77-92.
16. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210-216.
17. Zhu D, Corral LG, Fleming Y W, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57(12):1849-1859.
18. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771-4779.
19. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-687.
20. Pratt G, Goodyear O, Moss P. Immunodefciency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138(5):563-579.
21. Racanelli V, Leone P, Frassanito MA, et al. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 2010; 115(6):1185-1193.
22. Goodyear OC, Pratt G, McLarnon A, et al. Differential pattern of CD4+ andCD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined signifcance (MGUS) and multiple myeloma. Blood. 2008;112(8):3362-3372.
23. Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 2002;168(10):4914-4919.
24. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77(2):78-86.
25. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18):7347-7356.
26. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-825.
27. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335.
28. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276.
29. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51.
30. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
31. Richardson PG, Siegel D, Baz R, et al. Phase I study of pomalidomide MTD, safety and effcacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013; 121(11):1961-1967.
32. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-686.
33. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24(10):1769-1778.
34. Richardson PG, Hofmeister CC, Siegel D, et al. MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA, USA.
35. Baz R, Shain KH, Alsina M, et al. Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: report of the dose escalation cohort. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA, USA.
36. Berenson JR, Hilger JD, Klein LM, et al. A Phase 1/2 Study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA, USA.
37. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
38. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
39. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010; 24(11):1934-1939.
40. Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA, USA.
41. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-2975.
42. Leleu X, Attal M, Arnulf B, et al; Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121(11):1968-1975.
43. Short KD, Rajkumar S V, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906-908.
44. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/ refractory mm: a phase 3, multicenter, randomized, open-label study. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA, USA.